Improving the Standard of Care

Conference Correspondent  - Conference Correspondent, ASH

R. Donald Harvey believes that developing well-tolerated drugs is the key to improving the standard of care in managing patients with hematologic malignancies.

In general, in thinking about patients with hematologic malignancies, and how we might be able to improve standards of care, I think as we think about cancer as a whole, whether it's hematologic malignancies or solid tumors, the idea of trying to deepen responses and cure patients is important.

Helping to think about regimens and drugs that will give deep responses, sustained responses, and trying to do that in a way that will minimize side effects for patients. I work in the phase one clinical trials arena. For us, there are certain side effects that are concerning, but there are also side effects that are really more concerning to patients, like having nausea every day.

If you're going to take drugs for years on end, for example for the management of high blood pressure, they've got to be drugs that are well tolerated. Thinking in general about side effects prevention and management, and developing drugs that have better side effect profiles, are going to be pretty important to improve the care of all patients with hematologic malignancies.

Related Items
No Link between Long-Term Eltrombopag Treatment and Incidence of Cataracts in Adult Patients with Chronic ITP During EXTEND
Conference Correspondent  published on December 27, 2017 in ASH
Eltrombopag Treatment Improved Platelet Counts in Patients with Persistent or Chronic ITP
Conference Correspondent  published on December 27, 2017 in ASH
Fostamatinib-Treated Patients with Persistent/Chronic ITP Maintained Long-Term Responses
Conference Correspondent  published on December 27, 2017 in ASH
Avatrombopag Superior to Placebo for the Treatment of Chronic ITP
Conference Correspondent  published on December 27, 2017 in ASH
Subcutaneous Romiplostim Increased Platelet Response in Children with ITP
Conference Correspondent  published on December 27, 2017 in ASH
Centers for Disease Control and Prevention Guidelines on Opioid Use for Cancer Pain
Chase Doyle
TOP - August 2017, Vol 10, No 3 published on August 1, 2017 in Conference Correspondent, HOPA
Maintenance Chemotherapy After Hematopoietic Stem-Cell Transplantation
Chase Doyle
TOP - August 2017, Vol 10, No 3 published on August 1, 2017 in Conference Correspondent, HOPA
Graft-versus-Host Disease: Breakthroughs on the Horizon
Chase Doyle
TOP - August 2017, Vol 10, No 3 published on August 1, 2017 in Conference Correspondent, HOPA
Basket Clinical Trials: A New Era in Cancer Treatment
Chase Doyle
TOP - August 2017, Vol 10, No 3 published on August 1, 2017 in Conference Correspondent, HOPA
Burnout Rates High for Pharmacists in Hematopoietic Stem-Cell Transplantation
Chase Doyle
TOP - August 2017, Vol 10, No 3 published on August 1, 2017 in Conference Correspondent, HOPA
Last modified: December 5, 2017